Wells Fargo upgraded NeuroPace from Equal Weight to Overweight and set a new price target of $20.00 from $16.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/14/2024 | $16.00 → $20.00 | Equal Weight → Overweight | Wells Fargo |
| 1/30/2024 | $22.00 | Outperform | Leerink Partners |
| 11/10/2023 | $11.00 | Overweight | Cantor Fitzgerald |
| 8/24/2023 | $5.00 → $6.00 | Underweight → Equal-Weight | Morgan Stanley |
| 2/22/2023 | $10.00 | Buy | Lake Street |
| 4/6/2022 | $13.00 | Outperform | Wolfe Research |
| 3/11/2022 | $11.00 → $9.00 | Equal-Weight | Wells Fargo |
| 3/11/2022 | $15.00 → $12.00 | Outperform | SVB Leerink |
-- Grew revenue 28% year-over-year to $21.1 million in Q3 2024 -- -- Increased full-year 2024 revenue guidance to $78 million to $80 million -- -- Demonstrated continued operating discipline through further decrease in cash burn -- -- Management scheduled to host a conference call today at 4:30 p.m. ET -- MOUNTAIN VIEW, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update. Recent Highlights Reported record revenue of $21.1 million in the third quarter of 2024, a 2
The RNS System Post-Approval Study (PAS) is the largest prospective post-approval study in neuromodulation for patients with drug-resistant focal epilepsy The RNS System PAS evaluates safety and effectiveness of the RNS System in the adult focal population – the largest patient segment of drug-resistant epilepsy MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced Food and Drug Administration (FDA) submission of three-year safety and effectiveness data from its prospective Post-Approval Study (PAS) of the RNS System in adults with drug-resistant f
MOUNTAIN VIEW, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter of 2024 after market close on Tuesday, November 12, 2024. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at https://viavid.webcasts.com/starthere.jsp?ei=1690707&tp_key=080b652fbc. Individuals interested in participating in the call via telep
Morgan Stanley analyst Drew Ranieri maintains NeuroPace (NASDAQ:NPCE) with a Equal-Weight and lowers the price target from $9.5 to $8.
Gainers Embecta (NASDAQ:EMBC) shares increased by 37.7% to $14.14 during Thursday's regular session. The company's market cap stands at $814.1 million. As per the press release, Q2 earnings came out today. Seres Therapeutics (NASDAQ:MCRB) shares moved upwards by 36.28% to $1.02. The market value of their outstanding shares is at $154.2 million. The company's, Q1 earnings came out yesterday. G1 Therapeutics (NASDAQ:GTHX) shares rose 35.08% to $5.79. The company's market cap stands at $302.9 million. Vaccinex (NASDAQ:VCNX) shares rose 31.75% to $7.51. The market value of their outstanding shares is at $11.8 million. Zai Lab (NASDAQ:ZLAB) stock increased by 25.28% to $20.76. The company's
Cantor Fitzgerald analyst Ross Osborn reiterates NeuroPace (NASDAQ:NPCE) with a Overweight and maintains $18 price target.
4 - NeuroPace Inc (0001528287) (Issuer)
4 - NeuroPace Inc (0001528287) (Issuer)
4 - NeuroPace Inc (0001528287) (Issuer)
10-Q - NeuroPace Inc (0001528287) (Filer)
8-K - NeuroPace Inc (0001528287) (Filer)
10-Q - NeuroPace Inc (0001528287) (Filer)
-- Grew revenue 28% year-over-year to $21.1 million in Q3 2024 -- -- Increased full-year 2024 revenue guidance to $78 million to $80 million -- -- Demonstrated continued operating discipline through further decrease in cash burn -- -- Management scheduled to host a conference call today at 4:30 p.m. ET -- MOUNTAIN VIEW, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update. Recent Highlights Reported record revenue of $21.1 million in the third quarter of 2024, a 2
MOUNTAIN VIEW, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter of 2024 after market close on Tuesday, November 12, 2024. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at https://viavid.webcasts.com/starthere.jsp?ei=1690707&tp_key=080b652fbc. Individuals interested in participating in the call via telep
-- Revenue grew to $19.3 million in Q2 2024, a 17% increase over Q2 2023 -- -- Increased full-year 2024 revenue guidance to $76 million to $78 million -- -- Demonstrated continued operating discipline as evidenced by further decrease in cash burn -- -- Management scheduled to host a conference call today at 4:30 p.m. ET -- MOUNTAIN VIEW, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update. Recent Highlights Reported total revenue of $19.3 million in the s
SC 13G/A - NeuroPace Inc (0001528287) (Subject)
SC 13G/A - NeuroPace Inc (0001528287) (Subject)
SC 13G/A - NeuroPace Inc (0001528287) (Subject)
MOUNTAIN VIEW, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointment of Amy Treadwell as its new Vice President of Human Resources, effective immediately. "We are excited to have Amy join the team and help us continue to build an engaged, high-performing culture that supports our growth," said Joel Becker, Chief Executive Officer of NeuroPace. "We are at an important point in our growth with a number of significant commercial, operating, and technological opportunities in front of us. We believe Amy's appointment, along with the recent appointments
Appointed former key developer of RNS System as new Vice President of Research and Development Appointed former head of commercial marketing for Boston Scientific's DBS franchise as the new Vice President of Marketing MOUNTAIN VIEW, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointments of Brett Wingeier as the new Vice President of Research and Development and Katie Keller as the new Vice President of Marketing, effective immediately. "We are excited to welcome Katie and Brett to our team. Katie brings an understanding of the neurostimulation ma
NeuroPace Appoints Joel Becker as President & CEO Becker Brings a Track Record of Strong Commercial Execution and Deep Medical Device Operating Expertise Mike Favet to leave Company after four years as President, CEO and Board Member and will continue to advise through transition MOUNTAIN VIEW, Calif., June 28, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced the appointment of Mr. Joel Becker as NeuroPace President & CEO and member of the Board of Directors effective July 10, 2023. Mr. Michael Favet will be stepping down as CEO and as a member of NeuroPace'
Wells Fargo upgraded NeuroPace from Equal Weight to Overweight and set a new price target of $20.00 from $16.00 previously
Leerink Partners initiated coverage of NeuroPace with a rating of Outperform and set a new price target of $22.00
Cantor Fitzgerald initiated coverage of NeuroPace with a rating of Overweight and set a new price target of $11.00